Sunday, October 04, 2015 10:50:40 AM
The 14 years of being out there with no negative side effects is a very good thing. Weight loss would generally be considered a positive side effect, unless a person was emaciated, then Sucanon might not be a good choice for that individual. But then most type 2 diabetics are overweight and not underweight.
As for the future of Roth and Sucanon, this will be determined by expansion into new (countries) markets and resulting sales. There is a huge potential as type 2 diabetes is growing and becoming a world wide epidemic. There is a huge market that is only growing. I believe that once a major distribution agreement is signed and marketed successfully through doctors, hospitals and clinics, Sucanon sales and stock price will rise in lock-step. If /when this occurs it will be "off to the races" and many will be kicking themselves for not buying in at 1/2 cent.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM